The clinical trial, called by the acronym "Toler8" by the company, has the full title "An open-label, multi-center, first in human, phase 1/2a trial to evaluate the safety and preliminary efficacy of autologuous tolerogenic dendritic cells ex vivo loaded with recombinant factor VIII (FVIII) in adults with congenital hemophilia A (HA) with neutralizing antibodies to FVIII and having failed immune tolerance induction (ITI).

The abstract can be read here https://ashpublications.org/blood/article/140/Supplement%201/12733/487400/Trial-in-Progress-An-Open-Label-Multi-Center-First

For further information, please contact:

Christina Herder, Acting CEO, Idogen AB

Tel: +46 70374 71 56

E-mail: christina.herder@idogen.com

Certified Advisor:
Vator

The information was submitted for publication through the agency of the contact persons set out above on December 12, 2022 at 08:14 CET.

Idogen (Nasdaq First North Growth Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs or the body's own cells or tissue. The company's most advanced program, IDO 8 - now in clinical phase - is designed to restore the efficacy of hemophilia drugs in patients who have developed neutralizing antibodies.  For these hemophiliac patients, there is significant medical need for restoring the clinical effects of their treatment with factor VIII. This is a unique market positioning that over the long term could replace immune tolerance induction (ITI) treatments, with significant market potential. The planned IDO 8 clinical trial will validate the company's technology platform and facilitate a range of other applications in fields such as organ transplants (IDO T) and autoimmune diseases (IDO AID). More information about Idogen is available via https://www.idogen.com